Details of the Drug

General Information of Drug (ID: DMGFV3Z)

Drug Name
Nizatidine
Synonyms
Acinon; Antizid; Axid; Calmaxid; Cronizat; Distaxid; Galitidin; Gastrax; Naxidine; Niatidine; Nizatidina; Nizatidinum; Nizax; Nizaxid; Panaxid; Tazac; Ulcosol; Ulxid; Zanizal; Zinga; Axid Ar; Nizatidina [Spanish]; Nizatidinum [Latin]; Splendil ER; LY 139037; Acinon (TN); Axid (TN); LY-139037; Tazac (TN); ZE-101; ZL-101; Nizatidine (JAN/USP/INN); Nizatidine [USAN:BAN:INN:JAN]; N-(2-(((2-((Dimethylamino)methyl)-4-thiazolyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylamin; (E)-1-N'-[2-[[2-(dimethylaminomethyl)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; (E)-N-[2-[[2-(dimethylaminomethyl)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-N'-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({2-[(dimethylamino)methyl]-1,3-thiazol-4-yl}methyl)thio]ethyl}-N'-methyl-2-nitroethene-1,1-diamine
Indication
Disease Entry ICD 11 Status REF
Acid-reflux disorder DA22 Approved [1], [2]
Therapeutic Class
Antiulcer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 331.5
Topological Polar Surface Area (xlogp) 1.6
Rotatable Bond Count (rotbonds) 9
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Bioavailability
The bioavailability of drug is 70% [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 9.8 mL/min/kg [5]
Elimination
61% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 1 - 2 hours [5]
Metabolism
The drug is metabolized via the hepatic [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 15.08471 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.65% [5]
Vd
The volume of distribution (Vd) of drug is 0.8-1.5 L/kg [7]
Water Solubility
The ability of drug to dissolve in water is measured as 21.65 mg/mL [3]
Chemical Identifiers
Formula
C12H21N5O2S2
IUPAC Name
(E)-1-N'-[2-[[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine
Canonical SMILES
CN/C(=C\\[N+](=O)[O-])/NCCSCC1=CSC(=N1)CN(C)C
InChI
InChI=1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3/b11-6+
InChIKey
SGXXNSQHWDMGGP-IZZDOVSWSA-N
Cross-matching ID
PubChem CID
3033637
ChEBI ID
CHEBI:7601
CAS Number
76963-41-2
DrugBank ID
DB00585
TTD ID
D0Q9DK
VARIDT ID
DR00263
INTEDE ID
DR2187
ACDINA ID
D00477

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine H2 receptor (H2R) TTQHJ1K HRH2_HUMAN Antagonist [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [9]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Nizatidine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Minor Decreased absorption of Nizatidine due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [36]
Cefuroxime DMSIMD8 Moderate Decreased absorption of Nizatidine due to altered gastric pH caused by Cefuroxime. Acute bronchitis [CA42] [37]
Glibenclamide DM8JXPZ Moderate Decreased absorption of Nizatidine due to altered gastric pH caused by Glibenclamide. Acute diabete complication [5A2Y] [38]
Tolazamide DMIHRNA Moderate Decreased absorption of Nizatidine due to altered gastric pH caused by Tolazamide. Acute diabete complication [5A2Y] [38]
Glipizide DMZA5PQ Moderate Decreased absorption of Nizatidine due to altered gastric pH caused by Glipizide. Acute diabete complication [5A2Y] [38]
Posaconazole DMUL5EW Moderate Decreased absorption of Nizatidine due to altered gastric pH caused by Posaconazole. Aspergillosis [1F20] [39]
Aminophylline DML2NIB Moderate Decreased metabolism of Nizatidine caused by Aminophylline mediated inhibition of CYP450 enzyme. Asthma [CA23] [40]
Cefpodoxime DMJUNY5 Moderate Decreased absorption of Nizatidine due to altered gastric pH caused by Cefpodoxime. Bacterial infection [1A00-1C4Z] [37]
Bacampicillin DMP54C7 Moderate Decreased absorption of Nizatidine due to altered gastric pH caused by Bacampicillin. Bacterial infection [1A00-1C4Z] [37]
Cefditoren DMSUVM1 Moderate Decreased absorption of Nizatidine due to altered gastric pH caused by Cefditoren. Bacterial infection [1A00-1C4Z] [41]
Vismodegib DM5IXKQ Minor Decreased absorption of Nizatidine due to altered gastric pH caused by Vismodegib. Basal cell carcinoma [2C32] [42]
Pexidartinib DMS2J0Z Moderate Decreased absorption of Nizatidine due to altered gastric pH caused by Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [43]
Lapatinib DM3BH1Y Moderate Decreased absorption of Nizatidine due to altered gastric pH caused by Lapatinib. Breast cancer [2C60-2C6Y] [44]
HKI-272 DM6QOVN Major Decreased absorption of Nizatidine due to altered gastric pH caused by HKI-272. Breast cancer [2C60-2C6Y] [42]
Bosutinib DMTI8YE Moderate Decreased absorption of Nizatidine due to altered gastric pH caused by Bosutinib. Breast cancer [2C60-2C6Y] [44]
Oxtriphylline DMLHSE3 Moderate Decreased metabolism of Nizatidine caused by Oxtriphylline mediated inhibition of CYP450 enzyme. Cough [MD12] [40]
Itraconazole DMCR1MV Moderate Decreased absorption of Nizatidine due to altered gastric pH caused by Itraconazole. Fungal infection [1F29-1F2F] [45]
Ketoconazole DMPZI3Q Moderate Decreased absorption of Nizatidine due to altered gastric pH caused by Ketoconazole. Fungal infection [1F29-1F2F] [46]
GS-5885 DMSL3DX Moderate Decreased absorption of Nizatidine due to altered gastric pH caused by GS-5885. Hepatitis virus infection [1E50-1E51] [47]
Delavirdine DM3NF5G Moderate Decreased absorption of Nizatidine due to altered gastric pH caused by Delavirdine. Human immunodeficiency virus disease [1C60-1C62] [48]
Fosamprenavir DM4W9B3 Moderate Decreased absorption of Nizatidine due to altered gastric pH caused by Fosamprenavir. Human immunodeficiency virus disease [1C60-1C62] [49]
Rilpivirine DMJ0QOW Major Decreased absorption of Nizatidine due to altered gastric pH caused by Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [50]
Atazanavir DMSYRBX Major Decreased absorption of Nizatidine due to altered gastric pH caused by Atazanavir. Human immunodeficiency virus disease [1C60-1C62] [44]
Raltegravir DMYURI6 Minor Decreased absorption of Nizatidine due to altered gastric pH caused by Raltegravir. Human immunodeficiency virus disease [1C60-1C62] [51]
Ceritinib DMB920Z Moderate Decreased absorption of Nizatidine due to altered gastric pH caused by Ceritinib. Lung cancer [2C25] [52]
Dacomitinib DMOH8VY Moderate Decreased absorption of Nizatidine due to altered gastric pH caused by Dacomitinib. Lung cancer [2C25] [44]
Selpercatinib DMZR15V Major Decreased absorption of Nizatidine due to altered gastric pH caused by Selpercatinib. Lung cancer [2C25] [44]
Acalabrutinib DM7GCVW Moderate Decreased absorption of Nizatidine due to altered gastric pH caused by Acalabrutinib. Mature B-cell lymphoma [2A85] [53]
Ponatinib DMYGJQO Minor Decreased absorption of Nizatidine due to altered gastric pH caused by Ponatinib. Mature B-cell lymphoma [2A85] [42]
Dabrafenib DMX6OE3 Moderate Decreased absorption of Nizatidine due to altered gastric pH caused by Dabrafenib. Melanoma [2C30] [42]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Nizatidine and Thalidomide. Multiple myeloma [2A83] [42]
Siponimod DM2R86O Major Increased risk of bradycardia by the combination of Nizatidine and Siponimod. Multiple sclerosis [8A40] [42]
Fingolimod DM5JVAN Moderate Increased risk of atrioventricular block by the combination of Nizatidine and Fingolimod. Multiple sclerosis [8A40] [54]
Ozanimod DMT6AM2 Moderate Increased risk of atrioventricular block by the combination of Nizatidine and Ozanimod. Multiple sclerosis [8A40] [55]
Nilotinib DM7HXWT Moderate Decreased absorption of Nizatidine due to altered gastric pH caused by Nilotinib. Myeloproliferative neoplasm [2A20] [42]
Dasatinib DMJV2EK Major Decreased absorption of Nizatidine due to altered gastric pH caused by Dasatinib. Myeloproliferative neoplasm [2A20] [56]
Prasugrel DM7MT6E Minor Decreased absorption of Nizatidine due to altered gastric pH caused by Prasugrel. Myocardial infarction [BA41-BA43] [57]
Axitinib DMGVH6N Minor Decreased absorption of Nizatidine due to altered gastric pH caused by Axitinib. Renal cell carcinoma [2C90] [58]
Tolbutamide DM02AWV Moderate Decreased absorption of Nizatidine due to altered gastric pH caused by Tolbutamide. Type 2 diabetes mellitus [5A11] [38]
Chlorpropamide DMPHZQE Moderate Decreased absorption of Nizatidine due to altered gastric pH caused by Chlorpropamide. Type 2 diabetes mellitus [5A11] [38]
⏷ Show the Full List of 40 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 28 E00491 6097185 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ethanol E00023 702 Antimicrobial preservative; Penetration agent; Solvent
FD&C red no. 3 E00629 Not Available Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Magnesium stearate E00208 11177 lubricant
Potassium hydroxide E00233 14797 Alkalizing agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 25 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Nizatidine 150 mg capsule 150 mg Oral Capsule Oral
Nizatidine 300 mg capsule 300 mg Oral Capsule Oral
Nizatidine 75 mg tablet 75 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7248).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 075616.
3 BDDCS applied to over 900 drugs
4 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
8 Does the use of nizatidine, as a pro-kinetic agent, improve gastric emptying in patients post-oesophagectomy J Gastrointest Surg. 2009 Mar;13(3):432-7.
9 Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
10 DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB00585)
11 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
12 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
13 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
14 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
15 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
16 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
17 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
18 Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
19 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
20 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
21 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
22 Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
23 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
24 Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
25 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
26 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
27 Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
28 Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol. 2001 Feb;116(2):261-5.
29 Effect of nizatidine and cimetidine on betazole-stimulated gastric secretion of normal subjects: comparison of effects on acid, water, and pepsin. Am J Gastroenterol. 1988 Jan;83(1):32-6.
30 Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat. Arzneimittelforschung. 1997 Apr;47(4A):439-46.
31 Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Mol Pharmacol. 1995 Oct;48(4):774-82.
32 Effects of osutidine (T-593) and its enantiomers on gastric mucosal hemodynamics and mucosal integrity in anesthetized rats. Arzneimittelforschung. 2001 Jan;51(1):46-50.
33 Pharmacological profiles of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy] propyl] urea. Arzneimittelforschung. 1993 Feb;43(2):129-33.
34 New and Future Drug Development for Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2014 January; 20(1): 6-16.
35 Effects of IGN-2098, a new histamine H2-receptor antagonist, on gastric secretion and gastric and duodenal lesions induced in rats. Comparison with roxatidine. Nihon Yakurigaku Zasshi. 1992 Mar;99(3):167-80.
36 Albin H, Vincon G, Begaud B, Bistue C, Perez P "Effect of aluminum phosphate on the bioavailability of ranitidine." Eur J Clin Pharmacol 32 (1987): 97-9. [PMID: 3582475]
37 Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71. [PMID: 9784931]
38 Dey NG, Castleden CM, Ward J, et al "The effect of cimetidine on tolbutamide kinetics." Br J Clin Pharmacol 16 (1983): 438-40. [PMID: 6626438]
39 Alffenaar JW, van Assen S, van der Werf TS, Kosterink JG, Uges DR "Omeprazole significantly reduces posaconazole serum trough level." Clin Infect Dis 48 (2009): 839. [PMID: 19220151]
40 Anderson JR, Poklis A, Slavin RG "A fatal case of theophylline intoxication." Arch Intern Med 143 (1983): 559-60. [PMID: 6830388]
41 Product Information. Spectracef (cefditoren). TAP Pharmaceuticals Inc, Deerfield, IL.
42 Cerner Multum, Inc. "Australian Product Information.".
43 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
44 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
45 Blum RA, D'Andrea DT, Florentino BM, et al "Increased gastric pH and the bioavailability of fluconazole and ketoconazole." Ann Intern Med 114 (1991): 755-7. [PMID: 2012358]
46 Adachi M, Hinatsu Y, et.al "Improved dissolution and absorption of ketoconazole in the presence of organic acids as pH-modifiers." Eur J Pharm Sci 76 (2015): 225-30. [PMID: 25988287]
47 Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
48 Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
49 Product Information. Lexiva (fosamprenavir). GlaxoSmithKline, Research Triangle Park, NC.
50 Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
51 Product Information. Isentress (raltegravir). Merck & Company Inc, West Point, PA.
52 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
53 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
54 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
55 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
56 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
57 Product Information. Effient (prasugrel). Lilly, Eli and Company, Indianapolis, IN.
58 Product Information. Inlyta (axitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.